Preliminary in vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist

References

• Balimane, P.V., Han, Y.H., and Chong, S., 2006. Current industrial practices of assessing permeability and P-glycoprotein interaction. The AAPS journal, 8 (1), E1–13.
   PubMed Web of Science ®Google Scholar
• Bjornsson, T.D., et al., 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug metabolism and disposition: the biological fate of chemicals, 31 (7), 815–869.
   PubMed Web of Science ®Google Scholar
• Breivik, H., et al., 2006. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European journal of pain, 10 (4), 287–333.,.
   PubMed Web of Science ®Google Scholar
• Chien, C.C., and Pasternak, G.W., 1994. Selective antagonism of opioid analgesia by a sigma system. The journal of pharmacology and experimental therapeutics, 271 (3), 1583–1590.
   PubMed Web of Science ®Google Scholar
• Chien, C.C., and Pasternak, G.W., 1995. Sigma antagonists potentiate opioid analgesia in rats. Neuroscience letters, 190 (2), 137–139.
   PubMed Web of Science ®Google Scholar
• Chu, V., et al., 2009. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug metabolism and disposition: the biological fate of chemicals, 37 (7), 1339–1354.
   PubMed Web of Science ®Google Scholar
• Crespi, C.L., Miller, V.P., and Penman, B.W., 1997. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical biochemistry, 248 (1), 188–190.
   PubMed Web of Science ®Google Scholar
• Di, L., et al., 2011. Species independence in brain tissue binding using brain homogenates. Drug metabolism and disposition: the biological fate of chemicals, 39 (7), 1270–1277.
   PubMed Web of Science ®Google Scholar
• E. U. Clinical Trials Register. 2020a. An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, as part of an analgesic therapy balanced with morphine, followed by an open label extension, in the treatment of post-operative pain due to abdominal hysterectomy. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-003302-24/results: E. U. Clinical Trials Register [accessed 22 December 2020].
   Google Scholar
• E. U. Clinical Trials Register. 2020b. An exploratory, randomised, double-blind, placebo and active therapy-controlled, Phase I study, to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and food- effect of single and multiple ascending oral doses of EST73502 in healthy adults and patients with chronic, moderate, moderate-to-severe osteoarthritis pain. Study EudraCT Number 2018-000258-23.
   Google Scholar
• European Medicines Agency (EMA). 2012. Committee for medicinal products for human use (CHMP). Draft guideline on the investigation of drug interactions, June Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf [accessed 22 December 2020].
   Google Scholar
• Food Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). 2020, January. Draft guidance for industry. In vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions, Available from: https://www.fda.gov/media/134582/download. [accessed 22 December 2020].
   Google Scholar
• Garcia, M., et al., 2020. Discovery of EST73502, a dual µ-opioid receptor agonist and σ1 receptor antagonist clinical candidate for treatment of pain. Journal of medicinal chemistry, 63, 2434–2454.
   PubMed Web of Science ®Google Scholar
• Giacomini, K.M., et al., 2010. Membrane transporters in drug development. Nature reviews. drug discovery, 9 (3), 215–236.
   PubMed Web of Science ®Google Scholar
• Grimm, S.W., et al., 2009. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug metabolism and disposition: the biological fate of chemicals, 37 (7), 1355–1370.
   PubMed Web of Science ®Google Scholar
• Gris, G., et al., 2015. Sigma-1 receptor and inflammatory pain. Inflammation research, 64 (6), 377–381.
   PubMed Web of Science ®Google Scholar
• Gris, G., et al., 2014. S1RA, a selective sigma-1 receptor antagonist, inhibits inflammatory pain in the carrageenan and complete Freund’s adjuvant models in mice. Behavioural pharmacology, 25, 226–235.
   PubMed Web of Science ®Google Scholar
• Guengerich, F.P., 2006. Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS journal, 8 (1), E101–E111. https://link.springer.com/article/10.1208/aapsj080112
   PubMed Web of Science ®Google Scholar
• Gureje, O., et al., 1998. Persistent pain and well-being: a World Health Organization study in primary care. JAMA, 280 (2), 147–151.
   PubMed Web of Science ®Google Scholar
• Hu, M., et al. 2004. Use of Caco-2 cell monolayers to study drug absorption and metabolism. In: Yan Z., Caldwell G.W. eds. Optimization in drug discovery. Methods in pharmacology and toxicology. Totowa, NJ: Humana Press. https://doi.org/10.1385/1-59259-800-5:019
   Google Scholar
• Hughes, J.P., et al., 2011. Principles of early drug discovery. British journal of pharmacology, 162 (6), 1239–1249.
   PubMed Web of Science ®Google Scholar
• Instructions RED inserts devices. 2020. www.piercenet.com (89809 89810, 1794.2). Available from http://tools.thermofisher.com/content/sfs/manuals/MAN0011571_RED_Device_Insert_UG.pdf [accessed 22 December 2020].
   Google Scholar
• Kalvass, J.C., and Maurer, T.S., 2002. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharmaceutics & drug disposition, 23 (8), 327–338.
   PubMed Web of Science ®Google Scholar
• Kim, F.J., et al., 2010. Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Molecular pharmacology, 77 (4), 695–703.
   PubMed Web of Science ®Google Scholar
• Lahoz, A., et al., 2007. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. Toxicology in vitro: an international journal published in association with Bibra, 21 (7), 1247–1252.
   PubMed Web of Science ®Google Scholar
• Lu, A.Y., Wang, R.W., and Lin, J.H., 2003. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug metabolism and disposition: the biological fate of chemicals, 31 (4), 345–350.
   PubMed Web of Science ®Google Scholar
• Mei, J., and Pasternak, G., 2002. Sigma1 receptor modulation of opioid analgesia in the mouse. The journal of pharmacology and experimental therapeutics, 300 (3), 1070–1074.
   PubMed Web of Science ®Google Scholar
• Obach, R.S., Walsky, R.L., and Venkatakrishnan, K., 2007. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals, 35 (2), 246–255.
   PubMed Web of Science ®Google Scholar
• Ogilvie, B.W., et al., 2011. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug metabolism and disposition, 39 (11), 2020–2033.
   PubMed Web of Science ®Google Scholar
• Pan, Y.X., et al., 1998. Cloning and characterization of a mouse sigma1 receptor. Journal of neurochemistry, 70 (6), 2279–2285.
   PubMed Web of Science ®Google Scholar
• Parkinson, A., and Ogilvie, B., 2008. Casarett and Doull’s Toxicology: the basic science of poisons. Chapter 6. Biotransformation of xenobiotics, 131–160. https://accesspharmacy.mhmedical.com/book.aspx?bookID=2462
   Google Scholar
• Paul, S.M., et al., 2010. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature reviews. Drug discovery, 9 (3), 203–214.
   PubMed Web of Science ®Google Scholar
• Perloff, E.S., et al., 2009. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica; the fate of Foreign compounds in biological systems, 39 (2), 99–112.
   PubMed Web of Science ®Google Scholar
• PMDA. 2018. Ministry of Labor and Welfare. Guideline on drug interaction for drug development and appropriate provision of information, notification No.0723-4, pharmaceutical evaluation division, pharmaceuticals safety and environmental Health bureau, Japan. July 23, 2018. Available from: https://www.pmda.go.jp/files/000228122.pdf.
   Google Scholar
• Riley, R.J., Grime, K., and Weaver, R., 2007. Time-dependent CYP inhibition. Expert opinion on drug metabolism & toxicology, 3 (1), 51–66.
   PubMed Web of Science ®Google Scholar
• Rodrigues, A.D., 1999. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical pharmacology, 57, 465–480.
   PubMed Web of Science ®Google Scholar
• Stresser, D.M., 2004. High-throughput screening of human cytochrome p450 inhibitors using fluorimetric substrates.  In: Yan Z and G.W. Caldwell, eds. Optimization in drug discovery. methods in pharmacology and toxicology. Totowa, NJ: Humana Press, 215–230. Available at: https://doi.org/10.1385/1-59259-800-5:215 [accessed 22 Dec 2020].
   Google Scholar
• Tallarida, R., 2000. Drug synergism and dose-effect data analysis. New York: Chapman and Hall/CRC. https://doi.org/10.1201/9781420036107
   Google Scholar
• Tejada, M.A., et al., 2014. Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors. Psychopharmacology, 231 (19), 3855–3869.
   PubMed Web of Science ®Google Scholar
• Testa, B., Pedretti, A., and Vistoli, G., 2012. Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug discovery today, 17 (11–12), 549–560.
   PubMed Web of Science ®Google Scholar
• Vidal-Torres, A., et al., 2013. Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects. European journal of pharmacology, 711 (1–3), 63–72.
   PubMed Web of Science ®Google Scholar
• Walsky, R.L., and Obach, R.S., 2004. Validated assays for human cytochrome P450 activities. Drug metabolism and disposition: the biological fate of chemicals, 32 (6), 647–660.
   PubMed Web of Science ®Google Scholar
• Waters, N.J., et al., 2008. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. Journal of pharmaceutical sciences, 97 (10), 4586–4595.
   PubMed Web of Science ®Google Scholar
• Yan, Z., and Caldwell, G.W., 2001. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Current topics in medicinal chemistry, 1 (5), 403–425.
   PubMedGoogle Scholar
• Yeste, S., et al., 2020. Preliminary in vitro assessment of the potential of EST64454, a sigma-1 receptor antagonist, for pharmacokinetic drug-drug interactions. Biological & pharmaceutical bulletin, 43 (1), 68–765.
   PubMed Web of Science ®Google Scholar